Table 4.

Detection of CRC recurrence based on plasma mSEPT9 during follow-up.

No.	Gender	Age (years)	TNM staging	Treat	Period† (months)	S9		CEA (ng/mL)	Recurrence status
						Pre	Pos
1	Male	60	T3N0M0	S	26	+	-	3.1	NER
2	Male	56	T4aN2M0	S + C	26	+	+	153.4	Retroperitoneal lymph node metastases
3	Female	59	T4bN2M0	S + C	20	+	+	50.2	Lung metastases
4	Male	55	T4aN2M0	S + C + R	18	+	-	1.8	NER
5	Male	61	T4bN2M0	S + C	18	+	-	3.0	NER
6	Male	57	T4aN2M0	S + C	15	+	+	4.6	Liver metastases
7	Male	38	T4bN1M0	S + C + R	16	-	-	1.4	NER
8	Female	70	T2N0M0	S	18	+	-	3.0	NER
9	Female	49	T3N2M0	S + R	18	+	-	1.9	NER
10	Female	61	T4bN1M0	S + C + R	18	+	+	34.4	Liver metastases
11	Male	50	T4bN1M0	S + C	18	-	+	24.0	Liver metastases
12	Male	51	T3N0M0	S + C	18	+	-	1.6	NER
13	Female	64	T3N0M0	S + C	18	+	-	1.2	NER
14	Female	69	T4N2M0	S + C	6	+	-	1.7	NER
15	Female	51	T3N2M0	S + C	18	+	-	1.1	NER
16	Male	47	T4N2M0	S + C	17	+	-	3.6	NER
17	Male	51	T2N0M0	S	28	+	-	2.0	NER
18	Female	78	T4N0M0	S + C	6	+	+	1.5	Recurrent CRC

S9: methylated septin 9 DNA; Treat: treatment; S: curatively intended surgery; C: chemotherapy; R: radiation therapy; NER: no evidence of recurrence; +: positive; −: negative; boldface in CEA column represents positive; †: period after treatment.